EGFR and non-small cell lung carcinoma: Gefitinib is a molecular target drug that specifically blocks the tyrosine kinase activity of EGFR through preventing its autophosphorylation, and is approved for the treatment for patients with advanced non-small cell lung cancer (NSCLC)20–22.